New drug LB-P8 aims to tame rare liver disease PSC
Disease control
Recruiting now
This study tests a new drug, LB-P8, in 87 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if LB-P8 is safe and can lower levels of alkaline phosphatase (ALP), a marker of liver damage. Participants will receive either LB-P8 or a placebo,…
Phase: PHASE2 • Sponsor: LISCure Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC